Patent protection. Canadian drug firms boost R&D spending.

Drug firms' co-operation in clinical trials.

Canadian health spending.

Patent protection and licensing in microfluidics.

18 months sliced off Celebrex's patent protection.

Social protection spending and inequalities in depressive symptoms across Europe.

Canadian tobacco firms are ordered to pay £8bn for damage from smoking.

Thermodynamics of firms' growth.

The scope of patent protection for gene technology in China.

Trends in Prescription Drug Spending Leading Up to Health Reform.

European drug agency is exempting too many firms from testing drugs in children, cancer experts say.

Firms, crowds, and innovation.

"To patent or not to patent? the case of Novartis' cancer drug Glivec in India".

Association between spending on social protection and tuberculosis burden: a global analysis.

Transparency in Canadian public drug advisory committees.

Canadian approval sought for controversial pain drug.

Spending wisely.

Compulsory patent licensing and local drug manufacturing capacity in Africa.

Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.

Survey says leading firms support mammography.

Spending wisely.

Antiplasmodial drug targets: a patent review (2000 - 2013).

Supreme Court of India rejects Novartis’ cancer drug patent.

AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates.

Japan prepares spending increase.

Suggest Documents

Drug firms' co-operation in clinical trials.

Canadian health spending.

Patent protection and licensing in microfluidics.

18 months sliced off Celebrex's patent protection.

Social protection spending and inequalities in depressive symptoms across Europe.

Canadian tobacco firms are ordered to pay £8bn for damage from smoking.

Thermodynamics of firms' growth.

The scope of patent protection for gene technology in China.

Trends in Prescription Drug Spending Leading Up to Health Reform.

European drug agency is exempting too many firms from testing drugs in children, cancer experts say.

Firms, crowds, and innovation.

"To patent or not to patent? the case of Novartis' cancer drug Glivec in India".

Association between spending on social protection and tuberculosis burden: a global analysis.

Transparency in Canadian public drug advisory committees.

Canadian approval sought for controversial pain drug.

Spending wisely.

Compulsory patent licensing and local drug manufacturing capacity in Africa.

Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.

Survey says leading firms support mammography.

Spending wisely.

Antiplasmodial drug targets: a patent review (2000 - 2013).

Supreme Court of India rejects Novartis’ cancer drug patent.

AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates.

Japan prepares spending increase.

Patent protection. Canadian drug firms boost R&D spending.

Recommend Documents

Follow Us